- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.12. | Mizuho initiates Upstream Bio stock with Outperform rating on asthma drug potential | 3 | Investing.com | ||
| 17.12. | Upstream Bio: Mizuho startet Coverage mit "Outperform" dank Potenzial bei Asthma-Medikament | - | Investing.com Deutsch | ||
| 05.11. | Upstream Bio, Inc. reports Q3 results | 2 | Seeking Alpha | ||
| 05.11. | Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress | 161 | GlobeNewswire (Europe) | - Positive top-line results from VIBRANT Phase 2 trial of verekitug in CRSwNP reported in September showed statistically significant and clinically meaningful effects on primary and key secondary... ► Artikel lesen | |
| 05.11. | Upstream Bio, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 05.11. | Upstream Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 20.10. | Piper Sandler reiterates Overweight rating on Upstream Bio stock | 3 | Investing.com | ||
| UPSTREAM BIO Aktie jetzt für 0€ handeln | |||||
| 14.10. | Truist Securities initiates Upstream Bio stock with Buy rating on respiratory drug potential | 2 | Investing.com | ||
| 14.10. | Upstream Bio: Truist Securities startet Coverage mit Kaufempfehlung dank Potenzial bei Atemwegsmedikament | 1 | Investing.com Deutsch | ||
| 30.09. | Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug's Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress | 352 | GlobeNewswire (Europe) | - Data show verekitug prevents TSLP binding to the TSLP receptor by occupying ligand binding sites - - Additionally, findings show that verekitug outcompetes TSLP in the presence of preformed heterodimeric... ► Artikel lesen | |
| 09.09. | Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum | 1 | GlobeNewswire (USA) | ||
| 02.09. | Upstream Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.09. | Upstream Bio Reports Positive Top-line Results From Phase 2 VIBRANT Study | 7 | RTTNews | ||
| 26.08. | Piper Sandler reiterates Overweight rating on Upstream Bio stock | 2 | Investing.com | ||
| 06.08. | Upstream Bio, Inc. reports Q2 results | 1 | Seeking Alpha | ||
| 06.08. | Upstream Bio, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 06.08. | Upstream Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 28.07. | JPMorgan reiterates Overweight rating on Upstream Bio stock ahead of trial data | 3 | Investing.com | ||
| 08.07. | Upstream Bio startet Phase-2-Studie für COPD-Medikament Verekitug | 1 | Investing.com Deutsch | ||
| 08.07. | Upstream Bio begins phase 2 COPD trial for verekitug | 1 | Investing.com |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EDGEWISE THERAPEUTICS | 25,780 | +18,56 % | Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules | BOULDER, Colo., Dec. 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical... ► Artikel lesen | |
| QIAGEN | 38,985 | -0,35 % | QIAGEN N.V.: QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million | Return of approximately $500 million maximum approved by shareholders set to be completed on January 7, 2026 Capital return to be conducted through synthetic share repurchase combines a... ► Artikel lesen | |
| EVOTEC | 5,388 | +3,10 % | Gewinner für 2026: RZOLV Technologies, Evotec, Mutares haben es in sich - welche Entwicklungen sind entscheidend? | Das Börsenjahr 2025 war voll von spannenden Entwicklungen. Hausse auf den Rohstoffmärkten, Senkungen an der Zinsfront und geopolitische Spannungen. Manche Unternehmen, so wie Evotec hatten jedoch mit... ► Artikel lesen | |
| BIONTECH | 79,85 | 0,00 % | BioNTech Aktie: Wichtige Supportzonen - nun muss die Wende kommen | Trotz ordentlicher Nachrichten von BioNTech aus der Therapie-Pipeline ist die Biotech-Aktie zuletzt gefallen. Der Fehlausbruch an der 110-Dollar-Marke war charttechnisch ein Auslöser und im weiteren... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 37,360 | +0,03 % | Mineralys stock price target raised to $52 by Stifel on strong trial data | ||
| OLEMA PHARMACEUTICALS | 27,400 | -0,87 % | From Olema To Insmed: Are These High-Flying Biotechs Still Worth Buying? | LONDON (dpa-AFX) - The biotech sector continues to deliver headline-grabbing moves, with stocks surging to fresh highs and companies advancing pivotal trials, regulatory filings, and strategic... ► Artikel lesen | |
| INDAPTUS THERAPEUTICS | 2,670 | +35,53 % | Indaptus Therapeutics, Inc. - 8-K, Current Report | ||
| RECURSION PHARMACEUTICALS | 4,405 | +0,80 % | Cathie Wood's ARK sells Tesla stock, buys Coinbase and Recursion Pharmaceuticals | ||
| AVIDITY BIOSCIENCES | 72,23 | +0,15 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| COGENT BIOSCIENCES | 39,740 | -1,06 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 69,54 | -2,51 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity | SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| VERA THERAPEUTICS | 55,34 | +2,56 % | Vera Therapeutics stock price target raised to $66 by BofA Securities | ||
| VOR BIOPHARMA | 14,810 | +9,38 % | Vor Biopharma: Vor Bio Appoints RA Capital's Andrew Levin, M.D., Ph.D., and Forbion's Wouter Joustra to Board of Directors | ||
| ADMA BIOLOGICS | 19,480 | -0,10 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| REPARE THERAPEUTICS | 2,555 | +17,74 % | Repare-Aktie deutlich fester nach Asset-Verkauf an Gilead | Die Aktien von Repare Therapeutics haben am Mittwoch im vorbörslichen US-Handel kräftig zugelegt. Hintergrund ist eine Vereinbarung mit Gilead Sciences über den Verkauf eines Onkologie-Wirkstoffkandidaten.Gilead... ► Artikel lesen |
UPSTREAM BIO INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 30,210 Euro und damit +3,42 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu UPSTREAM BIO INC finden Sie auf Wallstreet Online.